Biotechnology News and Research

RSS

AEGEA completes $13.3M private equity financing

AEGEA Medical Inc., developer of a novel, minimally invasive treatment for abnormal uterine bleeding, reported today that it has completed a $13.3 million private equity financing led by Covidien Ventures.

30 Jun 2011

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

30 Jun 2011

Study about U.S. attitudes toward human embryonic stem cell research

While research using human embryonic stem cells has roused political controversy for almost two decades, little has been done to scientifically assess American attitudes on the subject. New research from the University of Nevada, Reno provides decision-makers with a much clearer picture of how their constituents truly feel about the subject.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Pregenen, Cellectis partner to develop meganucleases

Cellectis, the French genome engineering specialist, announced today the signing of a collaboration agreement with Pregenen, an American biotechnology start-up company dedicated to the creation of innovative tools for genome engineering.

30 Jun 2011

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

The Center of Innovation for Nanobiotechnology (COIN) has announced the upcoming NanoBio Executive Roundtable event to be hosted at The Hawthorne Inn in Winston-Salem, NC on July 14, 2011. This Roundtable will address a significant hurdle to nanobiotechnology development and commercialization—early-stage funding.

29 Jun 2011

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold Pharmaceuticals, Inc., today announced the initiation of a Phase 1/2 dose escalation clinical trial of TH-302 in combination with sunitinib in patients with advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumor (PNET).

29 Jun 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

New concepts for how evolutionary change occurs

At a recent Kavli Futures Symposium, 19 experts from a diverse range of fields discussed the promise of using the lab to understand and exploit the evolution of organisms -- progress that may one day lead to new vaccines or other biotechnology products.

29 Jun 2011

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc..

29 Jun 2011

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.

28 Jun 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

Nimbus Discovery closes $24 million Series A financing

Nimbus Discovery LLC, a biopharmaceutical company using state-of-the-art computational technology to discover novel medicines against exciting but previously inaccessible disease targets, today announced the close of a $24M Series A financing.

28 Jun 2011

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

Palatin Technologies, Inc. announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD).

28 Jun 2011

QIAGEN's common shares added to U.S. Russell indexes

QIAGEN N.V. today announced that its common shares were added to the U.S. large-cap Russell 1000 Index and the broad-market Russell 3000 Index.

From QIAGEN Manchester Limited 28 Jun 2011

University of Nottingham, Malaysian Government to co-host Crops for the Future Research Centre

The University of Nottingham Malaysia Campus is to co- host the first ever Crops for the Future Research Centre (CFFRC) in partnership with the Government of Malaysia.

28 Jun 2011

Biotechnology News and Research

AEGEA completes $13.3M private equity financing

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Study about U.S. attitudes toward human embryonic stem cell research

Researchers develop way to uncover evolution of human cancer cells

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Pregenen, Cellectis partner to develop meganucleases

COIN hosts ‘Risk vs. Reward: Financing Early-Stage, Emerging Technologies’ roundtable event

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Nuvilex to continue development of acquired live-cell encapsulation technology

New concepts for how evolutionary change occurs

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

AMRI, Proteros ink new partnership

Nimbus Discovery closes $24 million Series A financing

Enrollment commences in Palatin's bremelanotide Phase 2b trial for female sexual dysfunction

QIAGEN's common shares added to U.S. Russell indexes

University of Nottingham, Malaysian Government to co-host Crops for the Future Research Centre

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News